Ola Winqvist has more than 30 years of experience in immunological research and is a professor of cellular immunotherapy and chief physician in clinical immunology. He was previously chairman of the Swedish Immunology Association and is now chairman of the Swedish Medical Association's research delegation. The Cancer Foundation and the Swedish Research Council have continuously supported Olas research since 1999. He has also received various competitive grants from the European Union and the Swedish Agency for Innovation Systems for the Development of Immunological Therapy. Ola Winqvist is a specialist and Chief Physician in Clinical Immunology and has a doctorate from Uppsala University in Sweden. He has more than 30 patents and has started several spin-off companies. In 2013, his research was awarded the Athena Prize.

Other assignments: Chairman of the Delegation for research at the Swedish Medical Association and ImmunoWise AB. Board member of, among others, TLA Targeted Immunotherapies AB.

2021 – 2024 ISR Holding AB (publ), CFO

2014 – 2023 Implement Consulting Group, Partner

2001 – 2014 Capgemini, Miscellaneous management positions

1994 – 2001 Ernst & Young, Auditor and Consultant

1990 – 1994 Swedish Army, Reserve Officer

Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University of Rotterdam, Netherlands. He is significantly experienced in M&A and the pharmacutical industry, and spend 10 years at Merck Serono.

Dr Rohmann was also a Managing Partner of Nextech Venture in Switzerland, as well as responsible as Venture Capital Fund Manager for a Novartis Pharma AG. From 2010 to 2014 he was General Manager Europe for Burill & co, a Helthcare Venture Fund with more than $1.5 billion (USD) under management.

Jacob Harker has a BSc from University of Swansea, Great Britain. He has significant experience in the development of inhaled medicines with more than 20 years of industrial experience from Pfizer, AstraZeneca, PowderJect and Circassia. He also has extensive experience in leading CMC programmes, with focus on formulating and developing medicines by the means of particle technology for delivery via lungs, nasally and through the skin.

Nigel Goodman has a BSc in Pharmacology, Physiology and Microbiology from the University of Liverpool as well as a MBA from Manchester. He has a significant background in the development of innovative medicines with more than 35 years of industrial experience, from Hoffmann-La Roche in Great Britain and globally, and an American CRO. Since founding Gaea in 1994, and as the CEO of GaeaOÜ, a CRO based in Estonia, he has obtained extensive experience of the design and realization of global clinical studies for biotechnology companies.

CEO Singapore Ltd. An international businessman that is the advisor to the government of Moldavia. vice president of international affair TLA and CarryGenes

2017 – Now HiQ Bygg AB – CEO/Founder - Management consultant mainly in the construction and real estate industry.

2015 – 2017 WSP Management - Management consultant in the construction industry.

2011 – 2014 Ericsson AB - Logistics and NPI project manager for telecom equipment.

2005 – 2015 HiQ Bygg AB – CEO/Founder - Project Manager in the construction industry.

1998 – 2007 Ericsson AB - Production, development (RND), sourcing and project management.

1997 – 1998 ABB High Voltage Cables AB - Production and design for high voltage cables.

ISR: Shareholder since 2022. Invested in the company when he saw the opportunity to change the vaccination industry with a new platform that does not require injection, cold chains and healthcare staff.

2023 – Now Benteler Automotive Skultuna AB, CEO with 185 subordinates.

2019 – 2023 Benteler, Operation Manager in Eastern Europe with about 700 subordinates.

2017 – 2019 Benteler Automotive Skultuna AB - Manufacturing Manager with 110 reports.

2014 – 2017 Benteler Automotive Skultuna AB - Supply Chain Manger.

Benteler Skultuna has customers in Europe, Asia and North America and delivers directly

to major OEMs such as Volvo, BMW, Audi, Porsche and Daimler.

A total of 14 years of experience in the Automotive industry, both in Sweden and in Europe. Hence a large network in automotive both nationally and internationally.

ISR: Has been invested in ISR since the beginning of Covid and sees huge potential in ISR’s research.

2023 – 2024 Debe Drill Group, CEO

2023 – 2023 Debe Flow Group, Research And Development Manager

2016 – 2023 Megatec Information Technology AB, CEO (partner 2019-2021)

2016 – 2016 Speed Services AB, Sales and Marketing Manager

2010 – 2016 NordicFleet Management, Consultant in Fleet Management

ISR: Has been invested in ISR since the beginning of Covid and sees huge potential in ISR’s research.

2022 – Now QBR Systems AB, CEO/Founder. New container system for the shipping industry.

2016 – 2022 B Kubik Resurs AB, CEO/Founder of the Staffing Industry (Construction) Group.

At its peak, the Group had about 125 employees, with a piking turnover of about SEK 100 million.

The group was knocked out by the Covid-19 pandemic.

2008 – 2016 Scandinavian Screen Solutions AB, CEO/Founder

Import/purchase and sale of LED screens from China.

2002 – 2008 MCE Bild & Ljud AB (Radio-TV Shop), CEO/Founder. Turnover approx. 10 million SEK.

2022 – Now ISR-SMAFF Cooperative Society, Chairman

Approximately 300 members who jointly represent approximately 14% of the shares in ISR (approximately 11,500,000 shares).

ISR: With frequent travel to China during 2008 – 2016, interest in Hepatitis B was aroused.

ISR's HVB study was what made me invest in ISR as a company in 2019.